Future of Red Biotechnology in China

Product Code CCM00188
Publication Date April 2010
Publisher CCM International
Product Type Report
Pages 178
ISBN Number not applicable
Change currency
PDF £6,325.00 €7,617 $10,001 BUY >
PRINT £6,420 €7,731 $10,152 BUY >
CDROM £6,385 €7,689 $10,096 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Future of Red Biotechnology in China

Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?

Driven by its substantial environmental or economic benefits, China's RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China's RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?

What is covered in this report?

  • Overview of China's red biotechnology;
  • Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
  • Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
  • Profiles of major players and research institutes
  • Related policies and regulations

What benefits will you get?

  • Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China's red biotechnology;?
  • Keep informed of the precise development situation of key RB products with basic data and latest info;
  • Gain reasonable and constructive suggestions on market opportunities in China's RB fields;
  • Figure out, current trend and future growth prospect of red biotechnology in China;
  • Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.

Shenyang Sunshine Pharmaceutical Co., Ltd., Hualan Biological Engineering Inc., Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Kehua Bio-engineering Co., Ltd.

Contents

  • Executive summary
  • Methodology & sources
  • I Overview of red biotechnology in China
    • Introduction to red biotechnology
    • Role of red biotechnology in medicine industry
    • Overview of red biotechnology development
  • II Development environment of red biotechnology in China
    • II-1 Macro economic environment
    • II-2 Policy environment
    • II-3 Medicine industry development
    • II-4 Venture capital
  • III Market segments of red biotechnology industry in China
    • III-1 Gene recombinant drugs
    • III-1.1 Erythropoietin(EPO)
    • III-1.2 Insulin
    • III-1.3 G-CSF
    • III-1.4 Rh-GH
    • III-1.5 Interferon
    • III-1.6 Anti-tumor monoclonal antibody
    • III-2 Blood products
    • III-3 Human vaccines
    • III-4 Diagnostic reagent
    • III-4.1 Diagnostic reagent history in China
    • III-4.2 Current production situation in China
    • III-4.3 Producers information of Chinese diagnostic reagent
    • III-4.3.1 Biochemical diagnostic reagent
    • III-4.3.2 Immunodiagnostic reagent
    • III-4.3.3 Molecular diagnostic reagent
    • III-4.3.3.1 PCR reagent
    • III-4.3.3.2 Biochips
    • III-4.4 Forecast
    • III-5 Other red biotechnology based drugs
    • III-5.1 Antibiotic
    • III-5.1.1 Current antibiotic production in China
    • III-5.1.2 Penicillin production technology
    • III-5.1.3 Waste treatment technology
    • III-6 Forecast on supply & demand to the next 5~10 years
    • III-6.1 Forecast on gene recombinant market during 2010~2020
    • III-6.1.1 Supply of gene recombinant drugs during 2000~2020
    • III-6.1.2 Demand for gene recombinant drugs during 2009~2020
    • III-6.1.3 Difference between demand and supply during 2009~2020
    • III-6.2 Forecast on blood product market during 2010~2020
    • III-6.2.1 Supply of blood products during 2005~2020
    • III-6.2.2 Demand for blood products during 2009~2020
    • III-6.2.3 Difference between demand and supply during 2009~2020
    • III-6.3 Forecast on human vaccine market during 2010~2020
    • III-6.3.1 Supply of human vaccines during 2005~2020
    • III-6.3.2 Demand for human vaccines during 2009~2020
    • III-6.3.3 Difference between demand and supply during 2009~2020
    • III-6.4 Forecast on diagnostic reagent market during 2010~2020
    • III-6.4.1 Supply of diagnostic reagents during 2005~2020
    • III-6.4.2 Demand for diagnostic reagents during 2009~2020
    • III-6.4.3 Difference between demand and supply during 2009~2020
    • IV Cutting edge technology development in China
    • IV-1 Stem cell treatment
    • IV-2 Monoclonal antibody
    • IV-3 Diagnostic reagent
    • IV-4 Vaccine
  • V Geographical distribution of China's red biotechnology industry
    • V-1 Regional distribution
    • V-2 Introduction to RB industrial clusters
    • V-3 Overview of major RB industrial bases
    • V-3.1 Changsha Natioanl Biomedical Industrial Base
    • V-3.2 Zhangjiang National Biomedical Industrial Base
    • V-3.3 Zhongguancun National Biomedical Industrial Base
    • V-3.4 Shenzhen National Biological Industry Base
    • V-3.5 Changchun National Biological Industry Base
    • V-3.6 Guangzhou National Biological Industry Base
    • V-3.7 Shijiazhuang National Biological Industry Base
    • V-4 Forecast on national biological industry base in the next 5~10 years
  • VI Analysis of main Chinese companies in red biotechnology
    • VI-1 Choice of main Chinese companies in red biotechnology industry
    • VI-2 Analysis on main Chinese companies in red biotechnology industry
    • VI-2.1 Company engaged in biotech drugs
      • Shanghai FOSUN Pharmaceutical (GROUP) Co., Ltd.
    • VI-2.2 Companies engaged in blood products
      • Shanghai RAAS Blood Products Co., Ltd.
      • Hualan Biological Engineering,Inc.
    • VI-2.3 Company engaged in vaccine
      • Beijing Tiantan Biological Products Co.,Ltd.
    • VI-2.4 Company engaged in bio-engineering drugs
      • Beijing SL Pharmaceutical Co., Ltd.
    • VI-2.5 Company engaged in antibiotics
      • Shangdong Lukang Pharmaceutical Co.,Ltd.
    • VI-2.6 Company engaged in diagnostic reagents
      • Shanghai Kehua Bio-Engineering Co.,Ltd.
  • VII Main foreign involvement in China's red biotechnology
    • VII-1 Foreign companies in China
    • VII-1.1 GlaxoSmithKline (China) Co., Ltd.
    • VII-1.2 Pfizer (China) Co., Ltd.
    • VII-1.3 Novartis (China) Co., Ltd.
    • VII-1.4 Sanofi Pasteur (China) Co., Ltd.
    • VII-2 Comparison of foreign companies and Chinese companies
    • VII-3 Forecast of foreign involvement in China in next 5~10 years
    • VII-3.1 Forecast on Novartis expansion in China
    • VII-3.2 Forecast on GSK expansion in China
    • VII-3.3 Forecast on Sanofi-aventis expansion in China
  • VIII Analysis of investment in the next 5 years
    • VIII-1 Investment opportunities in biopharmaceutical industry
    • VIII-1.1 Solid foundation of bio-pharmaceutical investment
    • VIII-1.2 Investment hotspots in China
    • VIII-2 Risk analysis of the investment in China's red biotechnology
    • VIII-2.1 Risk from international environment
    • VIII-2.2 Risk from domestic environment
    • VIII-2.3 Estimation of bio-pharmaceutical investment risk in the next 5 years
  • IX Profiles of key players in China
    • IX-1 Companies
    • IX-1.1 Gene recombinant drugs
    • IX-1.2 Blood products
    • IX-1.3 Vaccine
    • IX-1.4 Diagnostic reagent
    • IX-2 Research institutes
  • List of Tables
    • Table II-1.1 Annual benchmark lending rate of RMB
    • Table II-2 Relevant policies on bio-pharmaceutical industry in China, 2006-2009
    • Table II-3.1 Medicine industry output value in China, 2004-2008, billion USD
    • Table III-1.1.1 Market share of major EPO manufacturers, 2009
    • Table III-1.2.1 Three generations of insulin
    • Table III-1.2.2 Main rh-insulin manufacturers in China, 2009
    • Table III-1.3.1 Output of some G-CSF manufacturers, 2008
    • Table III-1.4.1 Market share of main rh-GH manufacturers in China, 2006-2008
    • Table III-1.5.1 Top four interferon manufacturers in China, 2009
    • Table III-1.5.2 Market share of main interferon manufacturers in China, 2006-2008
    • Table III-1.6.1 List of imported anti-tumor monoclonal antibody drugs
    • TableIII-1.6.2 List of domestic anti-tumor monoclonal antibody drugs
    • Table III-2.1 Some major human albumin manufacturers in China, 2010
    • Table III-2.2 Human albumin output of major manufacturers in China, 2008-2009
    • Table III-2.3 Human immunoglobulin for intravenous injection output of major manufacturers, 2009
    • Table III-3.1 Vaccines belonging to National Immunization Program, 2010
    • Table III-3.2 Average import and export prices of human vaccines, 2006-2009
    • Table III-3.3 Production situation of H1N1 Influenza A Vaccine in China, 2010 (Unit: thousand doses)
    • Table III-3.4 Monthly lot release volume of top 4 H1N1 Influenza A vaccine in China, Sep-Dec. 2009 (Unit: thousand doses)
    • Table III-3.5 All Inactivated Split Influenza vaccine lot release in China, 2009
    • Table III-3.6 Situation of domestic HBV lot release, 2007-2009 (unit: thousand doses)
    • Table III-3.7 Major manufacturers' HBV lot release situation, 2009 (unit: thousand doses)
    • Table III-3.8 Lot release volume of some major human vaccines, 2007-2009
    • Table III-4.1 Comparison of three main diagnostic reagents
    • Table III-4.3.1 Major diagnostic reagent producers in China, 2008
    • Table III-4.3.1.1 Top 3 producers of biochemical diagnostic reagents in China, 2008
    • Table III-4.3.2.1 Some producers of immunodiagnostic reagent in China, 2008
    • Table III-4.3.3.1.1 Major PCR reagent producers in China, 2008
    • Table III-4.3.3.2.1 Some biochips producers in China, 2009
    • Table III-6.1.1.1 Supply of four gene recombinant drugs in China, 2000-2020
    • Table III-6.1.1.2 Supply of gene recombinant drugs in China, 2009-2020
    • Table III-6.1.2.1 Demand for gene recombinant drugs in China, 2009-2020
    • Table III-6.1.3.1 Demand & supply gap of gene recombinant drugs in China, 2009-2020
    • Table III-6.2.1.1 Supply of blood products in China, 2005-2020
    • Table III-6.2.2.1 Demand for blood products in China, 2009-2020
    • Table III-6.2.3.1 Demand & supply gap of blood products in China, 2009-2020
    • Table III-6.3.1.1 Supply of human vaccines in China, 2005-2020
    • Table III-6.3.2.1 Demand for human vaccines in China, 2009-2020
    • Table III-6.3.3.1 Demand & supply gap of human vaccines in China, 2009-2020
    • Table III-6.4.1.1 Supply of diagnostic reagents in China, 2005-2020
    • Table III-6.4.2.1 Demand for diagnostic reagents in China, 2009-2020
    • Table III-6.4.3.1 Demand & supply gap of diagnostic agents in China, 2009-2020
    • Table IV-3.1 Info about HIV diagnostic kit of different generation
    • Table V-1.1 Top 10 RB industrial regions by output value in China, 2008
    • Table V-1.2 Top 10 RB industry regions by profit, 2008
    • Table V-2.1 Seven National Biomedical Industrial Bases
    • Table V-3.1.1 Eight investment sectors of this Base
    • Table V-3.1.2.1 Incentives provided by the Base
    • Table V-3.1.2.2 High-quality research centers in the Base
    • Table V-3.2.2.1 Professional organizations
    • Table V-3.2.2.2 Venture Service Centre
    • Table V-3.3.2.1 Platform of Bio-technology
    • Table V-3.3.2.2 Animal base
    • Table V-3.3.2.3 R&D support
    • Table V-3.3.2.4 Main equipments and instruments in second-stage test workshop
    • Table V-3.5.1 Research centers
    • Table VI-1.1 Major listed bio-pharmaceutical companies and their achievements
    • Table VI-2.1.1 Employee structure in Shanghai FOSUN
    • Table VI-2.1.2 Business performance of Shanghai FOSUN by field and product, H1 2009
    • Table VI-2.1.3 Business performance of Shanghai FOSUN in different regions, H1 2009
    • Table VI-2.1.4 Financial indicators of Shanghai FOSUN, 2007- 2009
    • Table VI-2.2.1 Main products of Shanghai RAAS
    • Table VI-2.2.2 Employee structure of Shanghai RAAS
    • Table VI-2.2.3 Business performance of Shanghai RAAS by field and product, H1 2009
    • Table VI-2.2.4 Business performance of Shanghai RAAS in different regions, H1 2009
    • Table VI-2.2.5 Financial indicators of Shanghai RAAS, 2007 - 2009
    • Table VI-2.2.6 Employee structure of Hualan Biological
    • Table VI-2.2.7 Business performance of Hualan Biological by field and product, H1 2009
    • Table VI-2.2.8 Business performance of Hualan Biological in different regions, H1 2009
    • Table VI-2.2.9 Financial indicators of Hualan Biological, 2007- 2009
    • Table VI-2.3.1 Employee structure of Tiantan Biological
    • Table VI-2.3.2 Business performance of Tiantan Biological by product, H1 2009
    • Table VI-2.3.3 Business performance of Tiantan Biological, H1 2009
    • Table VI-2.3.4 Financial indicators of Tiantan Biological, 2007- 2009
    • Table VI-2.4.1 Employee structure of Beijing SL
    • Table VI-2.4.2 Business performance of Beijing SL by field and product, H1 2009
    • Table VI-2.4.3 Business performance of Beijing SL in different regions, H1 2009
    • Table VI-2.4.4 Financial indicators of Beijing SL, 2007-2009
    • Table VI-2.5.1 Employee structure of Shandong Lukang
    • Table VI-2.5.2 Business performance of Shandong Lukang by product, H1 2009
    • Table VI-2.5.3 Business performance of Shandong Lukang in different regions, H1 2009
    • Table VI-2.5.4 Financial indicators of Shandong Lukang, 2007- 2009
    • Table VI-2.6.1 R&D Events reflecting research capability of Shanghai Kehua, 2005~2009
    • Table VI-2.6.2 Four major diagnostic reagents of Shanghai Kehua
    • Table VI-2.6.3 Employee structure of Shanghai Kehua
    • Table VI-2.6.4 Business performance of Shanghai Kehua by field and product, H1 2009
    • Table VI-2.6.5 Business performance of Shanghai Kehua in different regions, H1 2009
    • Table VI-2.6.6 Financial indicators of Shanghai Kehua, 2007-2009
    • Table VII-1.1.2.1 Prescription medicines introduced by GSK China into China
    • Table VII-1.1.2.2 Vaccines introduced by GSK China into China
    • Table VII-1.1.2.3 OTC medicines marketed by GSK China in China
    • Table VII-1.1.2.4 Healthcare products of GSK China in China
    • Table VII-1.4.2.1 Bacterial diseases and viral diseases
    • Table VII-2.1 Financial performance comparison of Chinese and overseas biopharmaceutical companies, 2008-2009
  • Talbe VII-3.1.1 Industry sales and growth of Novartis, 2010~2015
    • Table VII-3.2.1 Industry sales and growth of GSK, 2009
    • Table VII-3.3.1 Sanofi-aventis industry sales and growth in 2008 and 2009
    • Table VIII-1.1.1 Main bio-industry policies
    • Table VIII-2.2.1 regulatory policies and main impacts
    • Table VIII-2.2.2 Important regulatory policies about blood product industry
    • Table VIII-2.2.3 Average R&D expenses of different era in the world
    • Table VIII-2.2.4 Domestic higher education graduates of biochemical pharmaceutical major
    • Table VIII-2.2.5 Employees of bio-chemical and bio-pharmaceutical enterprises
    • Table VIII-2.3.1 Estimated values of investment risks and EVBIR
  • List of Figures
    • Figure I.1 Output value of bio-pharmaceuticals in China, 2004-2009
    • Figure I.2 Proportion of bio-pharmaceuticals in China's medicine industry, 2009
    • Figure I.3 RB industrial output value changes in the proportion of China's GDP, 2004-2009
    • Figure II-1.1 China's GDP growth, 2004-2009
    • Figure II-2.1 Per capita disposable income of urban residents in China, 2004-2009
    • Figure II-3.1 Medicine industry output value in China, 2004-Nov.2009
    • Figure II-4 Procedure of venture capital in bio-pharmaceutical industry
    • Figure III-1.1.1 EPO market value in China, 1999-2009
    • Figure III-1.1.2 Forecast on EPO market value, 2010-2014
    • Figure III-1.2.1 Global l insulin market value structure, 2009
    • Figure III-1.2.2 Insulin market value structure in China, 2009
    • Figure III-1.2.3 Output of rh-insulin in China, 2007-2009
    • Figure III-1.2.4 Number of global diabetes patients, 1985-2007
    • Figure III-1.2.5 Number of diabetes patients in China, 1978-2007
    • Figure III-1.2.6 Market value of insulin in China, 2005-2009
    • Figure III-1.2.7 Insulin import and export under HS code 29371200 in China, 2006-2009
    • Figure III-1.2.8 Insulin import and export under HS code 30043100 in China, 2006-2009
    • Figure III-1.2.9 Forecast on insulin market value, 2010-2014
    • Figure III-1.3.1 Procurement value of G-CSF of all Chinese hospitals, 2004-2008
    • FigureIII-1.4.1 Output of rh-GH in China, 2006-2009
    • Figure III-1.4.1 Market value of rh-GH in China, 2004-2009
    • Figure III-1.4.3 Forecast on rh-GH output, 2010-2014
    • FigureIII-1.4.4 Forecast on rh-GH market value, 2010-2014
    • Figure III-1.6.1 Global market value of anti-tumor monoclonal antibody, 2000-2009
    • Figure III-1.6.2 Proportion of bio-pharmaceuticals market value in drug market, 2001-2007
    • Figure III-1.6.3 Proportion of anti-tumor monoclonal antibody market value in bio-pharmaceuticals market, 2007
    • Figure III-1.6.4 Rituximab market value in China, 2003-2008
    • Figure III-1.6.5 Trastuzumab market value in China, 2003-2008
    • Figure III-2.1 Geographical distribution of blood product manufacturers in China, 2009
    • Figure III-2.2 Output of human albumin in China, 2004-2009
    • Figure III-2.3 Average yield of human albumin in China, 2004-2008
    • Figure III-2.4 Number Changes in active human albumin producers, 2004-2009
    • Figure III-2.5 Human albumin market value in China, 2005-2009
    • Figure III-2.6 Lot release volume of imported human albumin, 2007-2009
    • Figure III-2.7 Forecast on human albumin output, 2010-2014
    • Figure III-2.8 Forecast on human albumin market value, 2010-2014
    • Figure III-3.1 Import and export situation of Chinese human vaccines, 2006-2009
    • Figure III-3.2 Vaccines import volume shares of import origins, 2009
    • Figure III-3.3 Market value of China's vaccine industry, 2006-2009
    • Figure III-3.4 Lot release volume of H1N1 Influenza A vaccine in China, 2009
    • Figure III-3.5 Forecast on China's H1N1 Influenza A vaccine output, 2010-2014
    • Figure III-3.6 Situation of domestic Inactivated Split Influenza vaccine lot release, 2007-2009
    • Figure III-3.7 Market capacity of Inactivated Split Influenza vaccine in China, 2007-2009
    • Figure III-3.8 Proportion of homemade and imported seasonal influenza vaccine in China, 2009
    • Figure III-3.9 Market share of seasonal influenza vaccine producers by volume in China, 2009
    • Figure III-3.10 Lot release volume of imported seasonal influenza vaccine in China, 2007-2009
    • Figure III-3.11 Forecast on China's influenza vaccine market capacity, 2010-2014
    • Figure III-3.12 Proportion of lot release volume of different HBV products, 2009
    • Figure III-3.13 China's HBV market capacity, 2007-2009
    • Figure III-3.14 Lot release volume of imported HBV in China, 2007-2009
    • Figure III-3.15 Forecast on HBV market capacity in China, 2010-2014
    • Figure III-4.2.1 Output value of RB industry and diagnostic reagents industry in China, 2005- 2009
    • Figure III-4.2.2 Share of different diagnostic reagents in China by output value, 2008
    • Figure III-4.4.1 Forecast on output value of diagnostic reagent in China, 2010-2015
    • Figure III-5.1.1.1 Output of four products in antibiotic industry in China, 2005-2009
    • Figure III-5.1.2.1 Major procedures of three steps fermentation technology for penicillin production
    • Figure III-5.1.3.1 Waste treatment procedure in Chinese antibiotic industry
    • Figure IV-1.1 Major procedure of diabetes treatment with stem cell
    • Figure IV-2.1 Major procedure of monoclonal antibody production
    • Figure IV-4.1 Major procedure of avian influenza vaccine production
    • Figure VIII-1.1.1 Chinese population and growth rate, 2000-2009
    • Figure VIII-1.1.2 Elderly population and its proportion, 2000-2009
    • Figure VIII-1.1.3 Per capital income and growth rate in urban areas
    • Figure VIII-1.1.4 Per capital income and growth rate in rural areas
    • Figure VIII-2.2.1 Exchange rate of CNY against USD
    • Figure VIII-2.2.2 Industrialization process of bio-pharmaceutical products